

## 2023 ASCO NEJ試験の発表

NEJ No.	Abstract Title	Abstract Number for Publication	Session Type	Session Title	Session Date and Time
NEJ025B	A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non-small-cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B.	9044	Poster Session	Lung Cancer Non-Small Cell Metastatic	6/4/2023 8:00 AM-11:00 AM
NEJ041	Satisfaction in older patients by geriatric assessment using a novel tablet-based questionnaire system: A cluster-randomized, phase III trial of patients with non-small-cell lung cancer (ENSURE-GA study; NEJ041/CS-Lung001).	12041	Poster Session	Symptoms and Survivorship	6/5/2023 1:15 PM-4:15 PM
NEJ043	A biomarker study of atezolizumab (atezo) + bevacizumab (bev) + carboplatin (carbo) + paclitaxel (pac) (ABCP) for patients with NSCLC harboring EGFR mutations (EGFRm) after failure of TKI therapy: NEJ043.	9079	Poster Session	Lung Cancer Non-Small Cell Metastatic	6/4/2023 8:00 AM-11:00 AM
NEJ057	First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).	9012	Rapid Abstract Session	Lung Cancer	6/5/2023 11:30 AM-12:30 PM